Invention Grant
US07897606B2 5,6-di-substituted oxadiazolopyrazines and thiadiazolopyrazines as CXC-chemokine receptor ligands
失效
作为CXC-趋化因子受体配体的5,6-二取代的恶二唑并吡嗪和噻二唑并吡嗪
- Patent Title: 5,6-di-substituted oxadiazolopyrazines and thiadiazolopyrazines as CXC-chemokine receptor ligands
- Patent Title (中): 作为CXC-趋化因子受体配体的5,6-二取代的恶二唑并吡嗪和噻二唑并吡嗪
-
Application No.: US11475789Application Date: 2006-06-27
-
Publication No.: US07897606B2Publication Date: 2011-03-01
- Inventor: Purakkattle J. Biju
- Applicant: Purakkattle J. Biju
- Applicant Address: US NJ Kenilworth
- Assignee: Schering Corporation
- Current Assignee: Schering Corporation
- Current Assignee Address: US NJ Kenilworth
- Agent Eric A. Meade; Henry C. Jeanette
- Main IPC: A61K31/4965
- IPC: A61K31/4965
Abstract:
Disclosed are compounds of the formula and the pharmaceutically acceptable salts thereof. The compounds are useful for the treatment of chemokine-mediated diseases such as COPD.
Public/Granted literature
- US20070015731A1 5,6-Di-substituted oxadiazolopyrazines and thiadiazolopyrazines as CXC-chemokine receptor ligands Public/Granted day:2007-01-18
Information query
